Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Urology Reports
Erschienen in: Current Urology Reports 12/2018

01.12.2018 | Urothelial Cancer (S Daneshmand, Section Editor)

Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy

verfasst von: Adnan El-Achkar, Luis Souhami, Wassim Kassouf

Erschienen in: Current Urology Reports | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of the Review

This review targets the latest literature on bladder preservation therapy with emphasis on trimodal therapy (TMT), highlighting its role in the management of muscle invasive bladder cancer (MIBC) and outlining future directions in bladder preservation research.

Recent Findings

TMT is the most promising bladder preservation treatment modality. Comparable results to contemporary radical cystectomy series are seen in properly selected patients. A multidisciplinary team approach is critical in the management of these patients. Future research is directed at the integration of immunotherapy into the treatment protocol.

Summary

TMT, involving maximal transurethral resection followed by chemoradiation, is an attractive alternative to radical cystectomy with urinary diversion in carefully selected patients with muscle invasive disease. In the absence of randomized trial (RCT), comparison between TMT and cystectomy, based on retrospective data from large centers, suggests comparable oncological outcomes, with a favorable impact on quality of life.
Literatur
1.
Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108.CrossRef
2.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.CrossRef
3.
Howlader N, N.A., Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA SEER cancer statistics review, 1975-2014, National Cancer Inst 2017.
4.
Gore JL, Litwin MS, Lai J, Yano EM, Madison R, Setodji C, et al. Use of radical cystectomy for patients with invasive bladder cancer. J Natl Cancer Inst. 2010;102(11):802–11.CrossRef
5.
Smith AB, Deal AM, Woods ME, Wallen EM, Pruthi RS, Chen RC, et al. Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base. BJU Int. 2014;114(5):719–26.CrossRef
6.
• Mak KS, et al. Quality of life in long-term survivors of muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2016;96(5):1028–36 A comparative retrospective study with the largest cohort that compares the quality of life of MIBC survivor patients treated with TMT vs RC. CrossRef
7.
•• Kulkarni GS, et al. Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. J Clin Oncol. 2017;35(20):2299–305 While the study has some inherent bias, this the first study to use propensity score matching analysis properly by accounting for important oncological factors when comparing RM vs TMT. CrossRef
8.
Hall E, H. S, Porta N, et al. BC2001 long-term outcomes: a phase III randomized trial of chemoradiotherapy versus radiotherapy alone and standard RT versus reduced high-dose volume RT in muscle invasive bladder cancer. J Clin Oncol. 2017;35(suppl 6S):280.CrossRef
9.
Cahn DB, Handorf EA, Ghiraldi EM, Ristau BT, Geynisman DM, Churilla TM, et al. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer. Cancer. 2017;123(22):4337–45.CrossRef
10.
Fischer-Valuck BW, et al. Treatment patterns and overall survival outcomes of octogenarians with muscle invasive cancer of the bladder: an analysis of the National Cancer Database. J Urol. 2017.
11.
Moonen L, v.d. Voet H, de Nijs R, Hart AAM, Horenblas S, Bartelink H. Muscle-invasive bladder cancer treated with external beam radiotherapy: pretreatment prognostic factors and the predictive value of cystoscopic re-evaluation during treatment. Radiother Oncol. 1998;49(2):149–55.CrossRef
12.
•• James ND, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477–88 Multicentre phase 3 trial confirmed that concurrent chemotherapy with radiation is superior to radiation alone. CrossRef
13.
Rodel C, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002;20(14):3061–71.CrossRef
14.
Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rödel CM, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol. 2014;66(1):120–37.CrossRef
15.
Caffo O, Thompson C, de Santis M, Kragelj B, Hamstra DA, Azria D, et al. Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: a pooled individual data analysis of eight phase I-II trials. Radiother Oncol. 2016;121(2):193–8.CrossRef
16.
Thompson C, Joseph N, Sanderson B, Logue J, Wylie J, Elliott T, et al. Tolerability of concurrent chemoradiation therapy with gemcitabine (GemX), with and without prior neoadjuvant chemotherapy, in muscle invasive bladder Cancer. Int J Radiat Oncol Biol Phys. 2017;97(4):732–9.CrossRef
17.
18.
Tran E, Souhami L, Tanguay S, Rajan R. Bladder conservation treatment in the elderly population: results and prognostic factors of muscle-invasive bladder cancer. Am J Clin Oncol. 2009;32(4):333–7.CrossRef
19.
Turgeon GA, Souhami L, Cury FL, Faria SL, Duclos M, Sturgeon J, et al. Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2014;88(2):326–31.CrossRef
20.
•• Giacalone NJ, et al. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital Experience. Eur Urol. 2017;71(6):952–60 The largest single center experience of TMT: showing the importance patient selection, and the oncological factors that affect survial in TMT treatment. CrossRef
21.
Krasnow RE, Drumm M, Roberts HJ, Niemierko A, Wu CL, Wu S, et al. Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder-sparing therapy. Eur Urol. 2017;72(1):54–60.CrossRef
22.
Mari A, Kimura S, Foerster B, Abufaraj M, D'Andrea D, Gust KM, et al. A systematic review and meta-analysis of lymphovascular invasion in patients treated with radical cystectomy for bladder cancer. Urol Oncol. 2018;36:293–305.CrossRef
23.
Hussain MH, et al. Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. J Urol. 2001;165(1):56–60 discussion 60-1.CrossRef
24.
Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014;32(34):3801–9.CrossRef
25.
Ritch CR, et al. Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle-invasive bladder cancer. BJU Int. 2017.
26.
Arcangeli G, Strigari L, Arcangeli S. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: a systematic review of clinical trials. Crit Rev Oncol Hematol. 2015;95(3):387–96.CrossRef
27.
Seisen T, Sun M, Lipsitz SR, Abdollah F, Leow JJ, Menon M, et al. Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2017;72(4):483–7.CrossRef
28.
• Fahmy O, et al. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol Oncol. 2018;36(2):43–53 The first metanalysis that compared outcomes of RC vs TMT while accounting for neoadjuvant chemoratherapy before either RC or TMT. CrossRef
29.
• Sanchez A, et al. Incidence, clinicopathological risk factors, management and outcomes of nonmuscle invasive recurrence after complete response to trimodality therapy for muscle invasive bladder cancer. J Urol. 2018;199(2):407–15 Largest single-center experience that focus on post TMT recurrence and treatment response. CrossRef
30.
Zietman AL, Grocela J, Zehr E, Kaufman DS, Young RH, Althausen AF, et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology. 2001;58(3):380–5.CrossRef
31.
Vashistha V, Wang H, Mazzone A, Liss MA, Svatek RS, Schleicher M, et al. Radical cystectomy compared to combined modality treatment for muscle-invasive bladder cancer: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2017;97(5):1002–20.CrossRef
32.
Eswara JR, Efstathiou JA, Heney NM, Paly J, Kaufman DS, McDougal WS, et al. Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. J Urol. 2012;187(2):463–8.CrossRef
33.
Ramani VA, et al. Differential complication rates following radical cystectomy in the irradiated and nonirradiated pelvis. Eur Urol. 2010;57(6):1058–63.CrossRef
34.
Iwai A, Koga F, Fujii Y, Masuda H, Saito K, Numao N, et al. Perioperative complications of radical cystectomy after induction chemoradiotherapy in bladder-sparing protocol against muscle-invasive bladder cancer: a single institutional retrospective comparative study with primary radical cystectomy. Jpn J Clin Oncol. 2011;41(12):1373–9.CrossRef
35.
Hafeez S, Warren-Oseni K, McNair HA, Hansen VN, Jones K, Tan M, et al. Prospective study delivering simultaneous integrated high-dose tumor boost (</=70 Gy) with image guided adaptive radiation therapy for radical treatment of localized muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2016;94(5):1022–30.CrossRef
36.
Kang JJ, Steinberg ML, Kupelian P, Alexander S, King CR. Whole versus partial bladder radiation: use of an image-guided hypofractionated IMRT bladder-preservation protocol. Am J Clin Oncol. 2018;41(2):107–14.PubMed
37.
Cowan RA, McBain CA, Ryder WDJ, Wylie JP, Logue JP, Turner SL, et al. Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(1):197–207.CrossRef
38.
Huddart RA, Hall E, Hussain SA, Jenkins P, Rawlings C, Tremlett J, et al. Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004). Int J Radiat Oncol Biol Phys. 2013;87(2):261–9.CrossRef
39.
40.
Goldsmith B, Baumann BC, He J, Tucker K, Bekelman J, Deville C, et al. Occult pelvic lymph node involvement in bladder cancer: implications for definitive radiation. Int J Radiat Oncol Biol Phys. 2014;88(3):603–10.CrossRef
41.
Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666–75.CrossRef
42.
Yafi FA, Aprikian AG, Chin JL, Fradet Y, Izawa J, Estey E, et al. Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int. 2011;108(4):539–45.CrossRef
43.
Tunio MA, Hashmi A, Qayyum A, Mohsin R, Zaeem A. Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience. Int J Radiat Oncol Biol Phys. 2012;82(3):e457–62.CrossRef
44.
Gray PJ, Fedewa SA, Shipley WU, Efstathiou JA, Lin CC, Zietman AL, et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol. 2013;63(5):823–9.CrossRef
45.
Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 1998;16(11):3576–83.CrossRef
46.
Mazeron JJ, Martin M, Brun B, Grimard L, Lelièvre G, Vergnes L, et al. Induction chemotherapy in head and neck cancer: results of a phase III trial. Head Neck. 1992;14(2):85–91.CrossRef
47.
Kun LE, Toohill RJ, Holoye PY, Duncavage JA, Byhardt RW, Ritch PS, et al. A randomized study of adjuvant chemotherapy for cancer of the upper aerodigestive tract. Int J Radiat Oncol Biol Phys. 1986;12(2):173–8.CrossRef
48.
Souhami L, Gil RA, Allan SE, Canary PC, Araújo CM, Pinto LH, et al. A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix. J Clin Oncol. 1991;9(6):970–7.CrossRef
49.
Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27(2):131–46.CrossRef
50.
Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace HJ III, Toonkel LM, et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology. 2009;73(4):833–7.CrossRef
51.
Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, et al. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys. 2003;57(3):665–72.CrossRef
52.
Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu CL, et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol. 2013;14(9):863–72.CrossRef
53.
Perdona S, et al. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. Cancer. 2008;112(1):75–83.CrossRef
54.
Arias F, Domı́nguez MA, Martı́nez E, Illarramendi JJ, Miquelez S, Pascual I, et al. Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program. Int J Radiat Oncol Biol Phys. 2000;47(2):373–8.CrossRef
55.
Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol. 2009;27(25):4055–61.CrossRef
56.
El-Achkar A, Kassouf W. Re: propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. Eur Urol. 2018;73(5):810–1.CrossRef
57.
•• Culp SH, et al. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol. 2014;191(1):40–7 The largest single-center experience that differentiated between high-risk and low-risk patients for RC. This study very well highlited the effect of patient selction on survival for RC. CrossRef
58.
Pietzak EJ, Sterling ME, Smith ZL, Malkowicz SB, Guzzo TJ. Outcomes of radical cystectomy in potential candidates for bladder preservation therapy. Urology. 2015;85(4):869–75.CrossRef
59.
Choudhury A, Nelson LD, Teo MTW, Chilka S, Bhattarai S, Johnston CF, et al. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res. 2010;70(18):7017–26.CrossRef
60.
Laurberg JR, et al. Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer. BJU Int. 2012;110(11 Pt C):E1228–36.CrossRef
61.
Chakravarti A, et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2005;62(2):309–17.CrossRef
62.
Choudhury A, et al. The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). Br J Cancer. 2017;116(5):649–57.CrossRef
63.
Shrivastava S, Mansure JJ, Almajed W, Cury F, Ferbeyre G, Popovic M, et al. The role of HMGB1 in Radioresistance of bladder cancer. Mol Cancer Ther. 2016;15(3):471–9.CrossRef
64.
Yang GL, Zhang LH, Bo JJ, Huo XJ, Chen HG, Cao M, et al. Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J Surg Oncol. 2012;106(1):57–61.CrossRef
65.
Wang W, et al. Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma. Oncol Lett. 2013;5(3):884–8.CrossRef
66.
Wu CT, Chen WC, Chang YH, Lin WY, Chen MF. The role of PD-L1 in the radiation response and clinical outcome for bladder cancer. Sci Rep. 2016;6:19740.CrossRef
67.
Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst. 2009;101(2):114–9.CrossRef
68.
Tanabe K, Yoshida S, Koga F, Inoue M, Kobayashi S, Ishioka J, et al. High Ki-67 expression predicts favorable survival in muscle-invasive bladder cancer patients treated with chemoradiation-based bladder-sparing protocol. Clin Genitourin Cancer. 2015;13(4):e243–51.CrossRef
69.
Hoskin PJ, Sibtain A, Daley FM, Wilson GD. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer. 2003;89(7):1290–7.CrossRef
70.
Koukourakis MI, Kakouratos C, Kalamida D, Bampali Z, Mavropoulou S, Sivridis E, et al. Hypoxia-inducible proteins HIF1alpha and lactate dehydrogenase LDH5, key markers of anaerobic metabolism, relate with stem cell markers and poor post-radiotherapy outcome in bladder cancer. Int J Radiat Biol. 2016;92(7):353–63.CrossRef
71.
72.
Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(11):1483–92.CrossRef
73.
Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312–22.CrossRef
74.
Bellmunt J, Powles T, Vogelzang NJ. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: the future is now. Cancer Treat Rev. 2017;54:58–67.CrossRef
75.
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26.CrossRef
76.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–29.CrossRef
Metadaten
Titel
Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy
verfasst von
Adnan El-Achkar
Luis Souhami
Wassim Kassouf
Publikationsdatum
01.12.2018
Verlag
Springer US
Erschienen in
Current Urology Reports / Ausgabe 12/2018
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-018-0859-z

Weitere Artikel der Ausgabe 12/2018

Current Urology Reports 12/2018 Zur Ausgabe

Urothelial Cancer (S Daneshmand, Section Editor)

Epigenetic Alterations in Bladder Cancer

Urothelial Cancer (S Daneshmand, Section Editor)

An Update in Enhanced Recovery Following Radical Cystectomy

New Imaging Techniques (S Rais-Bahrami and K Porter, Section Editors)

Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases

Lower Urinary Tract Symptoms & Voiding Dysfunction (J Sandhu, Section Editor)

Management of Lower Urinary Tract Symptoms After Pelvic Radiation in Females

Urothelial Cancer (S Daneshmand, Section Editor)

Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions

Urothelial Cancer (S Daneshmand, Section Editor)

Management of High-grade T1 Urothelial Carcinoma

Neu im Fachgebiet Urologie

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!

22.04.2024 | Prostatakarzinom | Nachrichten

Stufenschema weist Prostatakarzinom zuverlässig nach

20.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Varikozelen bei Jugendlichen: Das Für und Wider der Operation
weitere anzeigen

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen